Calidi Biotherapeutics, Inc.
CLDI
$0.415
-$0.016-3.71%
AMEX
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 2.21M | 3.07M | 3.61M | 4.01M | 5.86M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 4.03M | 5.23M | 5.77M | 6.75M | 9.82M |
Operating Income | -4.03M | -5.23M | -5.77M | -6.75M | -9.82M |
Income Before Tax | -4.15M | -5.07M | -5.76M | -7.22M | -8.23M |
Income Tax Expenses | 3.00K | -1.00K | 8.00K | 4.00K | -3.00K |
Earnings from Continuing Operations | -4.15M | -5.07M | -5.77M | -7.23M | -8.23M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | 51.00K | 15.00K | -- | -- | -- |
Net Income | -4.10M | -5.05M | -5.77M | -7.23M | -8.23M |
EBIT | -4.03M | -5.23M | -5.77M | -6.75M | -9.82M |
EBITDA | -3.93M | -5.12M | -5.67M | -6.65M | -9.72M |
EPS Basic | -0.27 | -0.65 | -1.40 | -2.03 | -2.31 |
Normalized Basic EPS | -0.17 | -0.40 | -0.68 | -1.27 | -1.44 |
EPS Diluted | -0.27 | -0.65 | -1.40 | -2.03 | -2.31 |
Normalized Diluted EPS | -0.17 | -0.40 | -0.68 | -1.27 | -1.44 |
Average Basic Shares Outstanding | 15.29M | 7.82M | 5.33M | 3.56M | 3.56M |
Average Diluted Shares Outstanding | 15.29M | 7.82M | 5.33M | 3.56M | 3.56M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |